Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
Submitted by
admin
on October 28, 2016 - 10:12am
Source:
Endpoints
News Tags:
FDA
AstraZeneca
durvalumab
clinical trials
head and neck cancer
Headline:
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
Do Not Allow Advertisers to Use My Personal information
